SecBot SecBot

LGVN drug pipeline

Longeveron Inc. · 1 rated drug
$2.14
−14.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.6%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
1
1 bearish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▼ bearish
Impact
PhasePhase 2
Time to marketNot stated

laromestrocel Updated Oct 26

What to watch

The next near-term event is the AHA 2026 Scientific Sessions podium presentation of the ELPIS II secondary endpoint data (date TBD). A positive reception could provide a short-term bounce, but the primary endpoint failure already limits the HLHS regulatory path. The bigger binary is the outcome of the strategic alternatives review, a sale or partnership could unlock value, while failure to find a deal could force a dilutive financing or a wind-down. Watch for 8-K filings for any 8-K regarding a potential sale, financing or Nasdaq compliance notice.

Bull case
  • Updated ELPIS II secondary endpoint analysis (Oct 26, 2026) showed a pre-specified secondary endpoint, Major Adverse Cardiac Events (MACE), achieved statistical significance with 8 events in the standard-of-care arm vs 1 in the laromestrocel arm (p=0.043), and the data was selected for a Late-Breaking Science podium presentation at AHA 2026 Scientific Sessions.
  • Phase 2b frailty results published in Cell Stem Cell (Feb 2026) showed laromestrocel improved physical condition in aging-related frailty patients at 9 months, and the company was selected as an XPRIZE Healthspan finalist.
  • Phase 2a CLEAR MIND Alzheimer's results published in Nature Medicine (March 2025) showed laromestrocel may reduce cognitive decline and brain atrophy; additional neuroinflammation data presented at AAIC 2026.
Bear case
  • ELPIS II Phase 2b (HLHS) missed its primary endpoint (RVEF at 12 months, p=0.8336), severely damaging the lead indication's regulatory path forward and triggered a strategic review of all options including a potential sale.
  • Cash runway extends only into Q4 2026 per the March private placement terms; with no revenue and a $4.7M quarterly net loss, the company likely needs additional capital soon, risking severe dilution.
  • Chief Medical Officer Dr. Nataliya Agafonova resigned effective Oct 14, 2026 with no replacement named, creating operational uncertainty in clinical execution.

Other drugs in filings and trials

no drug report yet
  • Lomecel-B medicinal signaling cells 1 trial

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
May 8, 2026laromestrocelFast Track−1.6%−21.2%
May 8, 2026laromestrocelOrphan drug designation−1.6%−21.2%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Lomecel-B medicinal signaling cellsEvaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.Phase 2Active not recruiting40Jun 30, 2026